Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

NACompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

January 10, 2024

Conditions
Type 2 Diabetes Mellitus (T2DM)Atrial Fibrillation (AF)
Interventions
DRUG

Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
collaborator

The Third Affiliated Hospital of Anhui Medical University

UNKNOWN

collaborator

The Second People's Hospital of Anhui Province

OTHER

collaborator

Hefei Second People's Hospital

UNKNOWN

lead

Shanghai Chest Hospital

OTHER

NCT06660134 - Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF | Biotech Hunter | Biotech Hunter